Pinatuzumab Vedotin (DCDT2980S, RG7593) Clinical Trials

TrialTitleStudy Record DetailPhaseSponsor/Colaborator
A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan and Evaluation of Combination DCDS4501A and Obinutuzumab in Patients With Non-Hodgkin’s LymphomaNCT01691898Phase IIGenentech, Inc./Roche, F. Hoffmann-La Roche Ltd. (Basel Switzerland)
A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin’s LymphomaNCT01209130Phase IGenentech, Inc./Roche, F. Hoffmann-La Roche Ltd. (Basel Switzerland)

Last Editorial Review: July 15, 2016